Natixis Adma Biologics, Inc. Transaction History
Natixis
- $18 Billion
- Q1 2025
A detailed history of Natixis transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Natixis holds 19,789 shares of ADMA stock, worth $390,239. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,789Holding current value
$390,239% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ADMA
# of Institutions
378Shares Held
188MCall Options Held
2.53MPut Options Held
696K-
Black Rock Inc. New York, NY18.6MShares$368 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.8MShares$332 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.9MShares$254 Million0.05% of portfolio
-
State Street Corp Boston, MA11.4MShares$226 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA5.67MShares$112 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.87B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...